Skip to content
Assyro AI
US FDA source recordWL · Warning Letter

Christopher Dale Butler — FDA Warning Letter

Issued to Christopher Dale Butler. Serious post-market compliance violation.

Product

Acidified Foods/Emergency Permit Control/Adulterated

Company

Christopher Dale Butler

Review center

CFSAN

Stage

Final Decision

Assyro regulatory brief

Free

Why did Christopher Dale Butler receive an FDA warning letter?

Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.

Verify in source

Source facts

FDA issued a warning letter to Christopher Dale Butler concerning Acidified Foods/Emergency Permit Control/Adulterated. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

Key details in this letter

  • 1Subject: Acidified Foods/Emergency Permit Control/Adulterated.
  • 2Issuing office: Human Foods Program.
  • 3No closeout letter was listed in the source metadata at refresh time.

Suggested next step

Review the exact FDA warning letter, cited violations, requested corrections, and any later response or closeout before assessing current status.

Open the document workspace

Built from structured FDA metadata and deterministic source-text signals. Topic matches are navigation aids, not legal or regulatory conclusions. Verify material decisions against the original FDA document.

FDAHTMLUpdated Jul 30, 2026

FDA source document

Read the full FDA warning letter

FDA publishes this warning letter as a web document.

Open the exact FDA source to read the complete letter and verify its current response or closeout status.

Open source on FDA.gov

Common questions about the Christopher Dale Butler warning letter

What does this warning letter mean for Christopher Dale Butler?

Serious post-market compliance violation. Public notice requiring prompt remediation. FDA issued this letter on January 9, 2026.

What happens after an FDA warning letter?

The firm is expected to respond in writing, normally within 15 working days, describing corrective actions and timelines. FDA verifies remediation — often through reinspection — and issues a closeout letter when violations are corrected. Unresolved warning letters can escalate to import alerts, seizure, or injunction.